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THE KAPPA OPIOID AGONIST, SALVINORIN A, ATTENUATES LOCOMOTOR EFFECTS OF MORPHINE
BUT NOT MORPHINE-INDUCED CONDITIONED PLACE PREFERENCE

Stacy Dianne Engebretson, M.A.
Western Michigan University, 2012

Salvinorin A (SA), a selective kappa opioid receptor agonist, is the main psychoactive
ingredient in the plant Salvia divinorum. The addiction potential of this naturally occurring
hallucinogen is currently under investigation using well-validated preclinical screening procedures,
including conditioned place preference (CPP). The primary aim of the current study was to
determine the effects of SA on CPP established by morphine in adult rats. A secondary aim was to

determine if the vehicle used to dissolve SA, dimethylsulfoxide (DMSO), influenced the outcome of
SA place conditioning. Rats were randomly assigned to one of four treatment groups: morphine (10

mg/kg) vs. saline; SA (0.4 mg/kg) + morphine (10 mg/kg) vs. DMSO + saline; DMSO vs. saline; SA (0.4
mg/kg) vs. DMSO. Rats were exposed to a 15-min habituation session for three consecutive days.
Daily 30-min place conditioning trials were conducted over the next eight days followed by a test
day. Morphine initially suppressed locomotor activity but activity increased with repeated exposure
to morphine, whereas the combination of SA and morphine reduced morphine-induced locomotor
activity. However, SA did not attenuate morphine-induced CPP. In a second experiment, CPP trials

were conducted with SA prepared in either a DMSO-water (3:1) solution or in an ethanol/TWEEN80

/water (1:1:8) solution. Regardless of the vehicle used, results of experiment 2 indicated that SA
failed to establish CPP and produced modest aversive effects.
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INTRODUCTION

Salvinorin Ais a relatively new hallucinogenic drug that acts as an agonist at the kappaopioid receptor. Derivatives ofthis compound are currently under investigation for potential

therapeutic use. Opioid receptor agonists have been traditionally used in the development of novel
pharmacotherapeutics for pain management, mood disorders and substance dependence

(Prisinzano, Tidgewell, and Harding, 2005; Hasebe et al., 2004; Carr and Lucki, 2010). By studying the
pyschoactive properties of kappa-opioid receptor (KOR) agonists, such as derivatives of salvinorin A,

a better use of antagonists may be developed to help treat patientswith psychological disorders
whosesymptoms resemble those seen with KOR activation. For instance, KOR agonists produce

disruptions in cognition and perception that resemble some ofthe symptoms of schizophrenia; these
effects can be blocked using KOR antagonists (Nemeth et al., 2010) and the schizophrenic-like
symptoms are resolved. Furthermore, there is some evidence to suggest salvinorin A, as well as

other k-opioid agonists, may have anti-depressant effects (Hanes, 2001; Braida, 2009), inspiring
prospective use of KOR agonists in the development of anti-depressant medication. Alternate

therapeutic uses of KOR agonists may be for opioid or psychostimuluant addiction rehabilitation.
Previous research has examined the attenuation effects of synthetic KOR agonists on the conditioned

rewarding effects of opioids (Huang et al., 2008) and psychostimulants (Tomasiewicz et al., 2008).
Preliminary research evaluating the ability of KOR agonists to attenuate the reinforcing effects of
other drugs of abuse is still ongoing.

In understanding the potential for salvinorin A to be used in such therapies, it is imperative

for public safety that the riskfor salvinorin A addiction be assessed using validated behavioral assays.
One validated method for studying addiction potential is to explore the inherent rewarding effect of
a drug through conditioned place preference (CPP). CPP repeatedly pairs a drug with a neutral

environment. Ifthe drug in question successfully converts the environment from a neutral stimulus

to a conditioned stimulus, then the environment will elicit a conditioned rewarding effect as
measured by increased time spent in that space compared to control. More research is needed to
conclude whether salvinorin A, by means of CPP, mayfunction as a conditioned reinforcer. The

present study utilized the CPP paradigm to determine if salvinorin Ais capable ofestablishing a

conditioned place preference. In addition, the present study also evaluated salvinorin A's ability to
attenuate the conditioned rewarding effects of morphine.
Origin and History of Salvia Divinorum

Salvia divinorum, or diviner's sage, is a species ofSalvia found in the mountains of Oaxaca,

Mexico (Valdes III, 1994). Salvia is a genus of plants in the mint family commonly known as "sage";
its name is derived from the Latin salvus, "to save," due to its alleged healing properties (USDA,
2012; Colins English Dictionary, 2012). Native tribal healers, Mazatec curanderos, use Salvia

divinorum as an aid in spiritual rituals to commune with God (Valdes III, 1994) and to treat a variety
of ailments including diarrhea, headaches, rheumatism and alcoholism (Prisinzano, 2005; Valdes III,
1984). Salvia divinorum grows in clones that extend over one meter high with blossoms of white

corolla and purple calyces above hollow square stems (Valdes III et al., 1983). Its defining features
are flowers, which makes classification difficult when they are not in bloom (Valdes III, 1994). After
successful identification, Salvia divinorum specimens were brought to the United States and Alredo

Ortega dubbed its main psychoactive ingredientas Salvinorin A. Later, salvinorin Awas isolated by
Leander Valdes (Valdes III et al., 1984). Other extractions, Salvinorin Bthrough F, were also isolated
by Valdes but were not shown to produce psychoactive effects (Valdes III, 1994). More details on
the chemical structure and variations of salvinorin A are discussed below.

Recreational and ritual use of Salvia divinorum or its main ingredient, salvinorin A, varies

depending on the preference of the user. People may drink a tea-like infusion, chew on a quid of
leaves, crush the leaves and ingest the resulting juice, smoke the leaves or inhale a vapor derived

from heating a leafs extracts, salvinorin A. Mazatec curanderos traditionally will collect fresh leaves
and crush the leaves finely and infuse them in water, making a bitter-tasting tea, orsometimes will

have patients eat the leaves (Valdes III, 1994). If preparing salvinorin Afor communion with spirits,
curanderos have found that infusions incorporating fewer than 20 pairs of leaves do not adequately
produce desired, hallucinogenic visions. For satisfactory hallucinogenic experiences, curanderos

suggest that infusions require 50 -100 leaves (Valdes III etal., 1983). Due tothe large requirement

of fresh leaves for hallucinations and the bitter-tasting infusions, original investigators speculated
that salvinorin Ahad a low abuse liability. However, recreational users in Mexico and USA smoke

dried leaves, which eliminates the effort of collecting a large number of fresh leaves (Valdes III,
1994). Moreover, less bitterstrains of the plant have been discovered and were cloned for
recreational use in the United States (Valdes III, 1994).

The potency of salvinorin Awas originally assessed to be similar to that of mescaline based

on open field testing in rodents, generalizing that human doses would range from 0.2 - 0.6 mg/kg
(Valdes III, 1994 ). However evidence from Siebert (1994) found that salvinorin Apotency in humans
may begreater than suspected. In a series ofexperiments, Siebert (1994) investigated discernible
psychoactive effects of salvinorin Athrough various routes of administration with human

participants. He reported that if participants swallowed leaves (dosing equivalent of10mg),

salvinorin Awas essentially inactive. Asolution of2 mg salvinorin Adissolved in 1 ml anhydrous
ethyl alcohol sprayed directly onto the lining of the mouth was reported to be a more effective route

ofadministration than swallowing leaves, though the salvinorin A-ethyl alcohol spray did not
produce reliable nor predictable effects, presumably because saliva rinsed away a majority ofthe
applied salvinorin A. Siebert (1994) found the mostdependable route to produce definite

psychoactive effects was to have participants chew and suck on leaves. Moreover, chewing and
sucking on 4-5 pairs of leaves similar to a coca-leaf quid maintained strongervisions which lasted a

longer period compared to other routes (Siebert, 1994; Valdes III, 1994).

A common recreational route of administering salvinorin A is to smoke dried Salvia

divinorum leaves yielding hallucinations in five to six inhalations (Valdes III, 1994). When inhaled, the

effects of salvinorin A have been characterized as an intense hallucination lastingfrom a few minutes
to up to two hours (Valdes III, 1994). Heating salvinorin Aand inhalation of the vapors has created

the most potent hallucinogenic experience, with effective doses rangingfrom 200-1000 pg (Valdes
III, 1994). With human volunteers, Siebert (1994) heated 200 -500 ug of salvinorin Aextracted from
Salvia divinorum leaves on a piece of foil and had participants inhale the vapors through a tube. The
resulting hallucinogenic experiences lasted anywhere from 30 minutes to two hours, with a

threshold of psychotropic effects at a dose of 200 pg. However, doses over 500 pg produced
delirium and required careful monitoring by the moderator (Siebert, 1994). Infact, regardless of
how salvinorin A was prepared, the reported hallucinogenic effects in humans last from 30 minutes
up to two hours, with the peak effects occurring approximately one hour after administration.

Currently salvinorin A is the most potent naturally occurring hallucinogen (Roth et al., 2002).
Pharmacology of Salvinorin A
The most abundant of source salvinorin A can be found within the resin of Salvia divinorum's

leaves; especially potent resin resides within the subcuticular space of a leafs grandular trichome

(tiny hair-like protrusions; Siebert, 2004). Once extracted, unlike other known hallucinogens (i.e., N,
/V-dimethyltryptamine, psilocybin, mescaline, lysergic acid diethylamide, or ketamine), salvinorin A
does not contain a nitrogen atom and thus is not categorized as an alkaloid (Roth et al., 2002).
Instead, salvinorin A is considered a neoclerodane diterpene, a bicyclicorganic compound composed
of four isoprene units. In fact, it is the first documented diterpene hallucinogen (Valdes III, 1994).
The unique molecular arrangement of salvinorin A may be the core to its psychoactive effects.

Extracts from another member of the Salviafamily, Salviasplenden, has a similar geometric figure to
salvinorin A. This extract, known as Splendin, has also been reported to have some pyschoactive
effects (Roth et al., 2002).

Salvinorin A's pharmacological target was first profiled by Roth et al. (2002) using cloned

human Gprotein-coupled receptors (GPCR) that contained a range of 48 molecular targets including
receptors, transporters and ion channels. After bathing the GPCR proteins with salvinorin A,
chemicals known to bind to individual receptors were applied. If the binding of a ligand was

inhibited, this indicated that salvinorin Ahad successfully attached to a particular receptor site. Due

to the known affinity ofthe applied ligands, the affinity ofsalvinorin Aat specific receptors was also
quantified.

Results of Roth's et al. (2002) receptor binding studies indicate that salvinorin A is a very

potent and selective KOR agonist. Although salvinorin Adid bind at mu and delta opioid receptors
(MOR and DOR, respectively) itdid not do soat any significant level. Chavkin et al. (2004) also
evaluated the potency ofsalvinorin Ausing radioligand binding, functional studies and through
measuring conductance ofGprotein-gated K+ channels. Their results confirm the original conclusion
of Roth et al. (2002) that salvinorin Ais a potent, full KOR agonist. Similar to other KOR agonists, in
vivo assays have previously found salvinorin Ato produce sedation and decreased motor
coordination in mice during inverted screen tasks (Fantegrossi et al., 2005), produceantinociceptive

effects in mice in tail flick and hot plate tests of nociception (John et al., 2006; McCurdy et al. 2006),
and increase immobility and decrease swimming behaviors of rats in a forced swim test (Carlezon et

al., 2006). In nonhuman drug discrimination studies, salvinorin Asubstitutes forthe discriminative
stimulus effects of synthetic KOR agonists like bremazocine, U-69593, and U-50488 (Butelman et al.,
2010; Baker et al., 2009) and produces distinct discriminative stimulus effects from MOR and delta

opioid receptor (DOR) agonists (Butelman et al., 2010), as well asother hallucinogens (Butelman et
al., 2010; Killinger et al., 2010; Peet and Baker, 2011). Braida et al. (2008) found salvinorin Amaintained lever pressing was blocked by delivery of a cannabinoid receptor antagonist, suggesting
that salvinorin A's effects are mediated through endocannabanoid system. However, Walentiny

(2010) proposed that cannabanoid activation at KORs, notsalvinorin Aactivation of

endocannabanoid receptors, may be responsible for Braida's et al. (2008) findings that cannabanoid
receptor antagonists attenuated salvinorin A-self administration.
Pharmacology of Morphine

Morphine is an active alkaloid isolated from opium, the dried sap found in the unripe seed
pods of Papersomniferum. Its molecular target is the opioid receptor. Opioid receptors are G-

protein coupled receptors commonly classified as one of three different subtypes, KOR, MOR and
DOR.

Activation of KOR, MOR, or DOR elicits analgesic effects, whereas psychotomimetic effects

are only obtained via activation of KOR and euphoric effects occur via MOR activation. One

suggestion is that the opposite effects of opioid receptors are due to arrangement of receptors and
anatomical position within the brain (Carlezan and Miczek, 2010).
Conditioned Place Preference

Conditioned place preference (CPP) utilizes Pavlovian conditioning principles to associate an
unconditioned stimulus (drug treatment) with a set of contextual stimuli (test chamber). Subjects
are exposed to an unconditioned stimulus (e.g. drug) just prior to being placed into a neutral
environment. The neutral stimulus (e.g. the environment) is associated with the unconditioned

response to the drug (e.g. reward or aversion) and the neutral stimulus becomes a conditioned
stimulus. As a conditioned stimulus, the environment will elicit a conditioned response associated

with the unconditioned effects of the drug (reward or aversion). If the drug produced reward, then
the conditioned environment will produce conditioned reward. The conditioned reward is measured

by a subject's preference for the drug-paired compartment compared to the vehicle-paired
compartment when the animal is in a drug-free state. Ifthe drug produced aversion, then the
conditioned environment will produce conditioned aversion. The conditioned aversion is measured

by a subject's avoidance for the drug-paired compartment compared to the vehicle-paired
compartment when the animal is in a drug-free state.

During CPP, a contiguous association is established; an immediate temporal contiguity exists
between the unconditioned and conditioned stimuli. Known reinforcers such as food (Spyraki et al.,

1982; Perks and Clifton, 1997)and water (Perks and Clifton, 1997),as well as some novel stimuli, will
establish place preferences (Bevins and Bardo, 1999). There is also a strong concordance between
drugs that establish CPP and reinforce self-administration of drug, including psychostimulants,

opioids and ethanol (as cited in table 1 of Bardo and Bevins, 2000; as cited inTzschentke, 1988).
There are a few limitations to the CPP paradigm. As Bardo and Bevins (2000) identify, CPP

may induce novelty-seeking on test days, although adequate exposure in both drug and vehicle
environments via habituation prior to conditioning trial, or providing a novel environment on test

day to serve as a novelty control should counteract this. Another limitation isthe individual's initial

preferencefor one context over another; the two methodologies to reduce this preference have
their own problems. If one pairsthe drug with the preferred context, a ceiling effect maydevelop in

assessing the extent of "preference" of an environment. If one pairs the drug with the non-preferred
context, the drug may be reducing an aversion instead of establishing preference. Other limitations

include the inability to determine a dose-effect curve within a single animal, requiring the use of a
large number of subjects for between subject comparisons.

However, Bardo and Bevins (2000) note several advantages to using CPP in preclinical drug

screening. It is usually sensitive to low doses, can sometimes be obtained using onlya single drug

pairing, measures both reward and aversion, can be tested when the animal is in a drugfree state,
does not require surgeries, CPP procedures typically yield a monophasicdose-effect curve in contrast
to the inverted U-shaped dose-effect curve produced by self-administration and finally CPP can
assess locomotor activity along with conditioned reward/aversion. Assessing locomotor activity is an

advantage to the CPP paradigm because there common relationship between the neural
mechanisms of drug-reward and locomotor activity and can be used as an additional dependent
measure or in correlation with conditioned place preference. CPP is also directly sensitive to
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alterations in motivational state, changes in reinforcer value, as well as taste aversion (Perks and
Clifton, 1997).

Katz and Gormezan (1979) note that CPP is a rapid and fairly inexpensive procedure

to measure drug-induced motivational processes.
Kappa and Mu Opioid Receptor Involvement in Reward Processing
MOR activation indirectly disinhibits secondary and tertiary dopaminergic neurons within the ventral
tegmental area (VTA; Margolis et al., 2003; Johnson and Roth, 1992). Figure 1 illustrates the

interaction between the GABAergic and dopaminergic neurons within the VTA in relation to MOR or

GABAergicneuron
with opiate receptor

Dopaminergic
neuron

Terminal neuron

Figure 1. Activation of mu- and kappa-opiate receptors on dopaminergic neurons. A) Without the
activation of opioid receptors. B) The mu-opiate receptor disinhibitory effect on dopaminergic
neurons. C) Kappa-opioid receptors direct inhibitory effect on dopamine release.
KOR activation. As shown in Figure 1A, GABA binds to its postsynaptic site on a dopaminergic cell.
This binding action opens CI- channels which polarizes the cell and inhibits the release of dopamine
at the synapse with the terminal neuron. Figure IB depicts how the activation of presynaptic MOR

receptors on a GABAergic neuron triggers a G-protein sequence which inhibits the release of GABA.

The resulting reduction of GABA at the dopaminergic neuron reverses the usual suppression of

dopamine release, thus increasing the availability of dopamine at the terminal neuron. Morphine
and MOR agonists applied directly to the VTA will establish the described increases in dopamine in
the NAc in a dose-dependent manner (Latimer et al., 1987) and produce a dose-related conditioned

place preference (Bals-Kubik et al., 1993; Spanagel et al., 1992). It is well established that increases in

the synaptic availability of dopamine, in particular increased activation of dopamine-Dl receptors in
the nucleus accumbens (NAc), mediates drug-induced conditioned place preference (Acquas et al.,
1989; Spanagel et al., 1992; Shippenberg et al., 1993).

In essence, as dopamine flow increases in the NAc, it influences the conditioned reinforcing
effects of contextual stimuli. If a dopamine antagonist, haloperidol, is injected into the NAc then
morphine-induced place preference is attenuated (Shippenberg et al., 1993).

6-OHDA lesions of the

NAc, the major termination site of A10 dopaminergic neurons from the VTA, will attenuate heroin-

induced conditioned place preference (Spyraki et al., 1983). Similarly, if subjects are given a

pretreatment of haloperidol prior to heroin injections then heroin-induced conditioned place
preference is attenuated (Spyraki et al., 1983). The administration of haloperidol will also block
place preference established by pairing a contextual stimulus with natural reinforcers, such as food
(Spyraki etal., 1982).

Unlike MOR agonists, KOR agonists tend to establish conditioned place aversion when

paired with contextual stimuli (Mucha and Herz, 1985; Shippenberg and Herz, 1991; Bals-Kubik et al.,

1993; Shippenberg et al., 1993). These effects are shown to be related to a dose-dependent
reduction in extracellular dopamine release after acute administration of KOR agonists (Gehrke and

Chefer 2008). In general, KOR agonists reduce extracellular dopamine by inhibiting the release of
dopamine from the VTA into the mesolimibic dopaminergic pathway (Bals-Kubiket al., 1993;

Spanagel et al., 1992; Margolis et al., 2003; Leyton et al., 1992). Specifically, KOR activation partially
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mediates dopamine release into the NAc (Ebner et al., 2010). As illustrated in Figure 1C, KOR
agonists activate G-protein-coupled inwardly rectifying potassium (GIRK) channels (Margolis et al.,

2003). GIRK channels are G-protein-gated ion channels that, when opened, allow the cell to become
more permeable to potassium, the cell hyperpolarizes and inhibit dopamine release. Hence, the
reduced flow of dopamine following KOR activation is a result of the direct inhibition of

dopaminergic neurons. The KOR-induced dopamine inhibition in the VTA can be blocked by
administering KOR antagonists (Margolis et al., 2003).

The general rule is that MORs disinhibit dopamine transmission and KORs inhibit dopamine
transmission, as explained prior, but this relation is only true in certain neurons. Although MOR and
KOR agonists typically act on either primary, secondary or tertiary dopaminergic neurons, Margolis et

al. (2003) note that neurons in the VTA can not fall under this simple classification, as there are an

extensive variety of receptor combinations and neurotransmitter possibilities. Margolis et al. (2003)

reported finding neurons that were "...MOR agonist-inhibited, KOR agonist-inhibited, inhibited by
both MOR and KOR agonists, and inhibited by neither" (P9984). In general, there are fewer KORs
than MORs both in the NAcand the VTA (Mansour et al., 1988), but the diversity of neurons within
the VTA produces a matrix of individual cell responses depending on the opioid receptors present on
a particular cell. Ford et al. (2006) suggested receptor sensitivity of VTA neurons is related to

projection sites. During KOR and MOR activation in the VTA, neurons fire differently depending on
their termination site. Specifically, a majority of KOR-sensitive neurons project into the NAc whereas
a majority of MOR-sensitive neurons project into the basolateral amygdala (Ford et al., 2006). Until
more research exposes the organization of individual neurons of the dopaminergic pathway,
investigating dopamine levels after drug administration within specific nuclei would be more

efficient than at the cellular level. However, measurements of neurochemical changes within

specific nuclei may also be inconclusive. There is an inconsistency within the literature concerning

whether KOR activation in the VTA (Bals-Kubik et al., 1993; Margolis et al., 2003; Leyton et al., 1992)
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or within the NAc (Spanagel et al., 1992; Shippenberg et al., 1993) is responsible for the overall
reduction of dopamine in the NAc. The spontaneous action of the VTA could differ between awake

and anesthetized animals and the different methods used in researching neurochemical changes in
these brain regions may account for these discrepancies. The alternative approach is utilizing
behavioral assays, which arguably is a more dependable method of predicting drug-related reward
rather than measuring responses at the neuronal level.

Generally, the rewarding and aversive effects of MOR and KOR agonists can be blocked by
pre-injections of MOR and KOR antagonists, respectfully (Acquas et al., 1989; Zhang et al., 2005;

Braida et al., 2008). Moreover, the behavioral effects of other drugs of abuse may be reduced bythe
co-administration of kappa opioid receptor (KOR) agonists. For instance, the KOR agonist U-69593
prevents cocaine-induced enhancement of brain stimulation reward (Tomasiewicz et al., 2008) and

the KOR agonist, U-50488, decreases cocaine-induced locomotor activity (Crawford et al., 1995). Of

special interest is the finding that U-5048- attenuates morphine-induced conditioned place
preference and locomotor activity (Huang et al., 2007).
Neuroanatomical Substrates of Conditioned Reward

Blockade of all dopamine transmission will attenuate rewarding as well as aversive

properties of place conditioning (Acquas et al., 1989) suggesting the behavioraleffect of conditioning
contextual stimuli is mediated by the dopaminergic system. However, operant administration of

natural rewards (i.e., food and water) in comparison to cocaine will produce different phasic firing of
dopaminergic neurons in the NAc (Carelli et al., 2000). In addition, animals that self-administer a

drug tend to have more dopamine release within the NAc compared to those with yoked drug

administration (Di Cano et al., 1998a). Acentral finding of conditioned reward is that regardless of

how a drug is paired with environmental stimuli, whether it is an active process via operant
administration or a passive, like yoked administration or place conditioning, an increase in NAc
dopamine release occurs. Di Caino et al.'s (1998a) study found dopamine levels for both self-
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administration and yoked administration groups increase by the same amount when the animal was

presented with a drug-paired, conditioned stimulus in a drug-free state. Further, post-conditioning
exposure to conditioned stimuli, while in a drug-free state, will produce increases motor activityand
a rise in extracellular dopamine levels in the NAc (Di Cano et al., 1998b).

SCIENTIFIC AIMS

The primary aim of the present study (experiment 1) was to determine if salvinorin A was

capable of attenuating morphine-established CPP similar to synthetic KOR agonist U-50488's
attenuation of morphine-induced CPP (Huang et al., 2007). This study also investigated the
conditioning effects of salvinorin Awhen administered alone. At least one laboratory has reported
that very low doses of salvinorin A are capable of establishing CPP (Braida et al., 2007; 2008).
However, typical results show that salvinorin A as well as synthetic KOR agonists produce

conditioned place aversion (Zhang et al., 2005; Shippenberg & Herz, 1987; Huang et al., 2007;
Walker, 2009). Onlytwo known studies (Braida et al., 2008; Walker, 2009) have assessed
conditioning effects of salvinorin A in CPP using rats, with conflicting results. However, it was noted
the two studies prepared salvinorin A in different vehicles. Braida et al. (2008) used an

ethanol/TWEEN80/sterile water mixture (1:1:8), whereas Walker (2009) used 75% dimethylsulfoxide
(DMSO), a polar aprotic solvent. Previous investigations in our laboratory have utilized DMSO as
salvinorin A's vehicle due to difficulties maintaining salvinorin A in an ethanol/TWEEN80/water

solution (Walker, 2009). Due to prior results of DMSO establishing conditioned place aversion, a
secondary aim (experiment 2) was to investigate the influence of the vehicle used to dissolve

salvinorin A on place conditioning. Therefore, experiment 2 systematically compared the
conditioning effects of salvinorin A prepared in two reported vehicles, DMSO/water and
ethanol/TWEEN80/water.
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EXPERIMENT 1

Methods

Subjects

Subjects were 36 adult, male Sprague Dawley rats obtained from Charles River Laboratories

(Portage, Ml). Subjects had prior experience with handling and had exposure to operant
conditioning, but were naive to conditioned place preference chambers, injections, and drug
treatment. Subject ages ranged from 4 months to 12 months old and were counterbalanced among
treatment groups. Animalswere singly housed in polycarbonate cages with corn cob bedding and ad

libitum access to food and water. Animal housing facilities were maintained on a 12/12-h, light/dark
cycle with the lights on from 0700 to 1900 and constant temperature (20±2°C).
Animals used in these studies were housed, handled, treated, and cared for in a humane and

ethical manner in accordance with NIH guidelines [Guide for the laboratory care and use of animals,
Eighth Edition. Accessible here http://oacu.od.nih.gov/regs/index.htm) and the animal use protocol
was reviewed and approved by the Western Michigan University Institutional Animal Care and Use
Committee.

Apparatus

Eight custom-designed chambers constructed from clear acrylic and were fitted within a
Versamax® animal monitoring system, equipped with infrared beams, which detected movement
along an XY coordinate plane (AccuScan Instruments, Columbus, OH). Each chamber measured 40

cm long X40 cm wide X40 cm high, at 0.5 cm thick, and was divided into two equal compartments

(40 X20 cm) by an acrylic wall. The wall had a 10 X10 cm opening to allow animals to pass between
compartments during habituation and testing sessions. The opening was covered with clear acrylic

during conditioning trials to restrict animal movement to one compartment. Each compartment
contained distinct visual and tactile cues. One compartment was equipped with black and white

horizontal lines on each wall and a smooth, aluminum floor with 1 cm diameter holesspaced 0.5 cm
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apart. The adjacent compartment was equipped with black and white vertical lines on each wall and
a textured plastic floor (Figure 2).

Figure 2. Place conditioning apparatus used in Experiment 1 and Experiment 2.

Drugs

Salvinorin A was synthesized by Dr. Thomas Munro and donated by Harvard McLean

Hospital (Belmont, MA). Salvinorin A (0.4mg/kg) solution was prepared fresh daily by dissolving it in
dimethysulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) and then diluting it with sterile water to

form a 75% DMSO solution. Morphine (10 mg/kg) was provided by the National Institute of Drug
Abuse (NIDA; Bethesda, MD) and was dissolved in 0.9% saline. Drugs were administered via
intraperitoneal (LP.) injection using 1 cc Monoject syringes at a 1 ml/kg injection volume.

Habituation Trials

Animals were acclimated to the chambers for 15 minutes a day for three consecutive days.
Animals were placed in the center of the chamber, in the center wall's opening, and were then
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allowed free access to both sides of the chamber for 15 minutes. Horizontal activity and time spent
in each compartment was recorded for each rat. On the last habituation trial, time spent in each
compartment was used to assign drug-compartment and vehicle-compartment during subsequent
conditioning trials. The compartment in which the animals spent the least amount of time was

designated as that individual's drug-paired side. For one squad (consisting of two animals per
treatment group), the drug side was inadvertently assigned to their preferred environment on
habituation day. This did not appear to influence the outcome of the study so the data for these
animals was not excluded from analysis.
Place Conditioning Trials

Rats were randomly assigned to one of the following four treatment groups: 10 mg/kg
morphine vs. saline (MOR, n = 9), 0.4 mg/kg salvinorin A vs. DMSO (SA, n = 9), 0.4 mg/kg salvinorin A

+ 10 mg/kg morphine vs. DMSO + saline (MOR + SA, n = 9), and DMSO vs. saline (DMSO, n = 9). The
MOR group and SA groups served as a control for the MOR + SA group. Due to inconsistent reports

in the literature concerning the conditioning effect of salvinorin A, the DMSO group functioned as
another control group to assess the conditioning effect of salvinorin A. Conditioning trials were
conducted in squads with a maximum of eight animals per squad, drug treatments were

counterbalanced among squads and chambers. All animals were injected within 5 minutes before
being placed in their assigned chamber for 30 min. Drug and vehicle conditions alternated daily.

Animals were given drug the first conditioning day, vehicle the second day and so forth for eight
consecutive days. Chambers were cleaned with lemon-scented cleaning wipes before and after
each squad.

CPP Test

The day following the last conditioning trial was designated as test day. The procedure was
the same as habituation day. Animals were allowed free access to either environment in the CPP

chamber as locomotor activity and time spent in each compartment was recorded.
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Statistical Analysis

All data were analyzed with IBM SPSS Statistics 20 (SPSS Inc., Chicago IL). Locomotor activity
was recorded as horizontal infrared beam breaks within the chamber during conditioningtrials. A

two factor repeated measures ANOVA was conducted on locomotoractivity, with injection type as a
between subjects factor and conditioning trial a within subjects factor. Bonferroni post hoc tests
were used to determine any significant differences between particular drug treatment groups. In

addition, the average activity across allfour drug conditioning trials was calculated for each group. A
one factor ANOVA and Bonferroni post-tests were conducted on these data to determine any
significant effect of drug treatment on activity. To assess the effects of conditioning on behavior

during the test trial, difference scores were determined for each animal by calculatingtime spent in
drug-compartment minus time spent in the vehicle-compartment. This measure is the most common

dependent variable for analyzing CPP (Bardo and Bevins, 2000). Aone factor ANOVA followed by
Bonferroni post-tests were conducted on the difference scores.

Results

Locomotor Activity

Figure 3 depicts the locomotor activity recorded during the eight conditioning trials.

Regardless of DMSO or saline, the highest locomotor activity was seen on the first conditioning day
followed by a steady decline in activity with repeated trials. In contrast, morphine-induced

locomotor activitysteadily increased with repeated dosing. Salvinorin Aappeared to suppress
locomotor activity relative to vehicle. Salvinorin A+ morphine produced the least amount of activity
compared to other treatment groups. A repeated measures ANOVA (treatment group, conditioning

trial) shows there was a significant main effect of conditioningday [F (7, 224) = 6.56, p < .0001], drug
treatment [F (3,32) = 3.51, p < .03 ]and a significant interaction between the drug treatment and
conditioning day [F (21, 224) = 6.23, p < .0001]. An additional one factor ANOVA was run on the

group average per drug conditioningtrial. Results of the one factor ANOVA found significant effect
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Figure 3. Mean (n = 9) locomotor activity per treatment group during drug and vehicle
conditioning in Experiment 1. Error bars represent standard error.
of drug treatment [F (3, 32) = 5.43, p < .01] and Bonferroni post-tests showed activity of the MOR

group was significantly different from that of the SA group (p<0.05) and the MOR+SA group (p<0.01).
This difference indicates that the co-administration of salvinorin A with morphine attenuated the
typical locomotor activity seen with morphine alone.

When excluding vehicle conditioning data from the analysis, repeated measures ANOVA

(treatment group, conditioning trial) reveals a significant main effect of drug treatment [F (3, 32) =
5.44, p < .01] and a significant interaction between the conditioning day and drug treatment [F(9,
96) = 9.86, p <.001]. A Bonferroni post-hoc analysis shows a significant difference between MOR and
MOR + SA (p = .006) and between MOR and SA (p = .016).
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Conditioned Place Preference

Conditioned place preference was calculated for individual animals by subtracting the time

spent on the vehicle-paired chamber from the time spent on the drug-paired chamber during the
CPP test. Group means (± S.E.M.) of difference scores are plotted in Figure 4. Bars in apositive

V£H

ITOR

SA

sA/aicm

Treatment Group

Figure 4. Experiment 1conditioned place preference for the drug-paired chamber on test day.
Error bars represent standard error. #Represents statistically significant from VEH group and *
represents statistically significant from SA group.

direction indicate place preference (i.e., more time spent in drug-paired chamber), whereas bars in a
negative direction indicate place aversion (i.e., less time spent in the drug-paired chamber). Results

of aone factor ANOVA found asignificant effect of drug treatment on chamber preference during
test day [F (3, 32) =71.67, p<0.001]. Results were further examined using Bonferroni post-hoc tests.

As depicted in Figure 4, significant differences were found between MOR +SA and DMSO (p<.001),
MOR +SA and SA (p<.001), MOR and DMSO (p<.001), and MOR and SA (p<.001). That is, subjects in

the DMSO and SA groups tended to spend less time in their designated drug compartment compared
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to subjects in the MOR and MOR + SA groups who displayed CPP for the drug-paired environment.
There was no statisticallysignificance between the SA and DMSO groups or between the MOR + SA
and MOR groups. However, there was a slight increase in time spent on the drug side for rats in the
MOR + SA group (M=719.64,SD=117.94) compared to those in the MOR group {M= 553.73, SD=
281.23).

EXPERIMENT 2

Introduction

Results of Experiment 1 indicated that salvinorin A produces conditioned place aversion.

These results are consistent with those of Zhang et al. (2005) but are inconsistent with the findings of
Braida et al. (2008), who reported that low doses (0.001 mg/kg - 0.04 mg/kg) of salvinorin A
produces conditioned place preference. Prior studies investigating place conditioning of salvinorin A
utilized an ethanol/TWEEN80/water (1:1:8) mixture to dissolve SA (Zhang et al., 2005, Braida et al.,
2008). However, results of Experiment 1 of the present study utilized DMSO vehicle due to
difficulties in our laboratory maintaining salvinorin A in an ethanol/TWEEN80/water solution. These

difficulties were confirmed by a previous report of uneven distributions of SA when prepared in
TWEEN80 (Valdes III, 1994). Walker (2009) also used a 75% DMSO solution in attempts to replicate

Braida's et al. (2008) study. Walker (2009) investigated a low dose of salvinorin (0.04 mg/kg; S. C.)
within the range that Braida et al. (2008) reported established CPP as well as at a ten-fold higher
dose. Contradictory to Braida et al. (2008), Walker (2009) found both doses of salvinorin A

established conditioned place aversion. Experiment 1 in the present study found 0.4 mg/kg
produced modest conditioned place aversion, supporting Walker's (2009) results. In addition,
Experiment 1 revealed that DMSO alone established conditioned place aversion relative to saline,

making it difficultto determine whether salvinorin A prepared in this manner induced place aversion
due to the aversive properties of DMSO or due to the effects of salvinorin A. Therefore, to assess
whether the results of Braida et al. (2008) and Walker (2009) were due to the different vehicles
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employed, Experiment 2 systematically compared the place conditioning of salvinorin Adissolved in
DMSO versus ethanol/TWEEN80 /water.

Methods

Subjects and Apparatus

Subjects were 32 experimentally naive, adult, male Sprague Dawley rats obtained from

Charles River Laboratories (Portage, Ml). Housing and animal care were described in Experiment 1.
The apparatus used in Experiment 2 was the same apparatus described in Experiment 1.
Drugs

Preparation of salvinorin A in DMSO was the same as in Experiment 1. Forcomparison,
salvinorin A (0.4mg/kg) was also prepared daily in ethanol, TWEEN80, and sterile water (1:1:8
proportion by volume).

Habituation, Conditioning and Test Trials

Animals were randomly assigned to one of five treatment groups: DMSO vehicle vs. saline
(DMSO, n =6), ethanol/TWEEN80/water vehicle vs. saline (TWN80, n = 6), Salvinorin A in DMSO vs.
DMSO vehicle (0.4mg/kg; SA + DMSO, n = 7), Salvinorin A in ethanol/TWEEN80/water vs.

ethanol/TWEEN80/water vehicle (0.4mg/kg; SA + TWN80, n = 7) and finally a saline vs. saline control
group (SAL, n = 6). The habituation, conditioning and testing procedures were the same as in
experiment 1.

Statistical Analysis

All data were analyzed with IBM SPSS Statistics 20 (SPSS Inc., Chicago IL). Locomotoractivity
during conditioningtrials and difference scores obtained from test trial were analyzed the same as in
experiment 1.
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Results

Locomotor Activity

All treatment groups exhibited the most locomotor activity on the first conditioning day, with a
steady decrease in locomotor activity across conditioning trials (Figure 5). Thistrend was seen
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Figure 5. Experiment 2 mean (n = 5, 6) locomotor activity per treatment group during
conditioning trials. Error bars represent standard error.

both for drug conditioning days and for vehicle conditioning days. A repeated measures ANOVA

(treatment group, conditioning trial) revealed a significant main effect of conditioning day [F (7,133)
= 15.71, p < .001] but no significant effect of treatment group or interaction between group and trial.
Bonferroni post-tests were not significant.
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Conditioned Place Preference

As seen infigure 6, difference scoreswere calculated and plotted similar to Experiment 1.

_

600n

-600-1
DMSO

SA + DMSO

SA + TWN 80

TWEEN80

SAL

Treatment Group

Figure 6. Experiment 2 conditioned place preference for the drug-paired environment. Error

bars represent standard error. * Represents statisticallysignificant from DMSO.

The DMSO vs. saline treatmentgroup spent more time in the saline-paired compartment, indicating
a conditioned aversion to the compartment paired with DMSO injections. All other treatment groups
showed no evidence of conditioned place preference or aversion. Results of a one factor ANOVA

showed a significant main effectof drugtreatment [F (4, 27) = 6.16, p <0.01]. Bonferroni post-hoc
tests showed a significant difference between SAL and DMSO (p < 0.001) and between DMSO and

TWN80 (p< .05). Regardless ofthe vehicle used to dissolve salvinorin A, resulting place conditioning
was almost identical: the mean difference score for the SA + DMSO group was -117.51 sec (SD =

202.45) and it was -110.80 sec (SD =225.88) forthe SA +TWN80 group. Neither group was
significantly different from the saline-treated group (M = 219.07, SD =238.97).
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DISCUSSION

Results of Experiment 1 found that 0.4 mg/kg salvinorin Aproduced conditioned place
aversion. Thesefindings are consistent with those of Zhang et al. (2005), who reported salvinorin A

produced conditioned place aversion in mice, and are consistent with those of Braida et al. (2008),
who reported salvinorin Aat higher doses produced conditioned place aversion in rats. However,
Braida et al. (2008) also reported that extremely low doses of salvinorin A established conditioned

place preference. Walker (2009) attempted to replicate Braida's et al. (2008) study and found that
salvinorin Aproduced conditioned place aversion, even at the low doses Braida et al. (2008)
reported to produce conditioned place preference. It is possible that the discrepancy between
Walker's (2009) and Braida's et al. (2008) results is due to the vehicle used to dissolve salvinorin A.

This supposition is supported somewhat by current findings that DMSO seemed to establish a

conditioned place aversion as other published studiesof CPP using DMSO have not explored DMSO
compared to a saline control. To investigate this possibility further, experiment 2 systematically
compared the place conditioningeffects of salvinorin A (0.4 mg/kg) dissolved in two different
vehicles. Experiment 2 found salvinorin A dissolved in 75% DMSO induced conditioned aversion

almost identical to salvinorin Adissolved in an ethanol/TWEEN80/water vehicle. Although it is
important to note that salvinorin A may have slightlyattenuated DMSO-conditioned aversion,

whether this result was related analgesic effects or potential rewardingeffects KOR activation is
unknown.

Therefore, the results from Experiment 2 suggest that the discrepancies between Braida et
al. (2008) and Walker (2009) were independent of the vehicle used. However, it should be noted

that Braida et al. (2008) and Walker (2009) both administered drugvia subcutaneous injection
whereas the current study administered drug via intraperitoneal injection (LP). Another difference

was Braida's et al. (2008) use of Wistar rats, whereas Walker (2009) and the present study used
Sprague-Dawley rats. Zhang et al. (2005) employed a dose of 1.0 mg/kgand 3.2 mg/kgsalvinorin A
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in the aforementioned ethanol/TWEEN80/water mix (LP.) using mice and reported conditioned place
aversion.

Rat strain and route of administration should be explored in future research.

The lack ofconsistent findings in the pre-clinical examinations ofsalvinorin A's abuse liability
raises questions concerning the recreational use of salvinorin Ain humans. Typically, other

hallucinogenic drugs (e.g., LSD) are not self-administrated in nonhumans, nor do they produce
conditioned place preference in nonhumans. Thus, CPP may not be an adequate assay of human
abuse potential for hallucinogens. Like other hallucinogens, human use of salvinorin Amay be

related to its heavy influence on priming (Weil, 1998; Valdes III, 1994) and changes in sensitivity to
other sensory cues like light and sound (Valdes III et al., 1983). Curanderos would instruct the
patient on how to navigatetheir visions, explaining what they will experience, and send them to a

dark and quiet place to encounter spiritual visitations (Valdes III et al., 1983; Valdes III, 1994). Valdes
(1994) notesthat, "The curandero spent hours before each session describing what we would see.
This had a tremendous influence on my second experience" (p. 9). Valdes (1994) also reported that
during his investigation of Mazatec rituals, the more intense and longer lasting visions occurred
when the setting was dark and quiet. In a personal account, Valdes (1994) noted that when the

Mexican village was noisy, the visions were infrequent and concentration was needed to "bring
back" images. However, once he settled that night to sleep in a dark and quiet room, the visions
returned at full strength. These observations bring about questions concerning the role of other
sensory perceptions in understanding the sensitivity of salvinorin A's effects. Unfortunately, the
human subjective drug experience is difficultto replicate in animal models.

Locomotor activity in addition to condition place preference testing is also commonly used
in preclinical screening of CNS active drugs and assists in determine the pharmacological actions of
novel compounds. The current study isthe first known study to demonstrate that salvinorin A

significantly attenuates morphine-induced locomotor activity. These findings are consistent with

reports that a synthetic KOR agonist, U-50488, decreases morphine-induced locomotor activity
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(Huang et al., 2007) as well as cocaine-induced locomotor activity (Crawford et al., 1995). Reduction
in morphine-induced locomotor activity by a KOR agonist is likely related to the ability of KOR
agonists to reduce dopamine levels in the NAc. Zhang et al. (2005) reported both decreases in

morphine-induced locomotor activity and decreases in extracellular dopamine afteradministration

of salvinorin A. Typically, drugs that increase NAc dopamine also increase locomotor activity.
Locomotor activity can be stimulated by direct increases in dopamine into the NAc. This effect is

blocked by dopamine antagonists injected into the NAc and amplified by amphetamines (Pijnenburg
et al., 1975). Although both locomotor activity and place conditioning have been previously shown
to be mediated by drug-induced increases in dopamine levels, the present study found that 0.4
mg/kg salvinorin Aattenuates MOR-induced locomotor activity, butfailed to inhibit MOR mediated

place conditioning, suggesting these behaviors can be pharmacologically altered independent ofone
another. However, it is possible that higher doses ofsalvinorin Aare required to block MOR-induced
CPP.

Ebner (2010) reported that 0.25 mg/kg salvinorin Adid not alter extracellular levels of

dopamine in the NAc, but 2.0 mg/kg significantly suppressed dopamine release into the NAc
compared to vehicle. Moreover, Zhang et al. (2005) showed that higher doses of salvinorin Athat

produced place aversion (1.0 mg/ kg and 3.2mg/kg; LP.) were accompanied by significant
suppression ofdopamine release. Furthermore, at least two otherstudies have found synthetic KOR
agonists attenuate morphine-induced CPP. For example, Huang et al. (2007) co-administered U-

50488 (8 mg/kg; LP.) with morphine (10 mg/kg; LP.) andeliminated morphine-induced conditioned

preference and established conditioned place aversion. In a similar study, Bolanos et al. (1996)

found a pretreatment ofU-50488 (2-10 mg/kg; S. C.) prior to injections ofmorphine (0.1 mg/kg to8

mg/kg; LP.) blocked morphine-induced CPP in rats 10-17 days old, but not for rats 35 days old.
Provided synthetic KOR agonists and salvinorin Aare comparable in potency and efficacy, a stronger
dose of salvinorin Acould yield results comparable to the U-50488 seen in Huang et al. (2007) and

•
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Bolanos et al. (1996). In an investigations employing a drug discrimination task to compare
salvinorin Ato synthetic KOR agonists, Baker et al. (2009) reported similar potencies between U50488 and salvinorin A. Although equivalent in behavioral potency, the efficacy at opening GIRK
channels differs between synthetic KOR agonists and salvinorin A. When comparing the potassium
conductance through GIRK channels, Chavkin et al. (2004) found salvinorin Ato be more efficacious

than its synthetic rival, U-50488. Because more efficacious drugs tend to be more selective,

salvinorin Acould interactdifferently at opioid receptors than synthetic KOR agonists.
Future researchshould focus on the direct comparisons between syntheticKOR agonists and
salvinorin A, especially ifthey are to be consideredfor use in therapeutic treatments. If these

compounds act similarly, then it can be assumed higher doses salvinorin Awill suppress dopamine
release into the NAc and may be considered for use in addiction research. Ifsyntheticvs. natural
compounds act differently on neurons projectingto other regions of the brain, such as the NAc,

knowing the disparities between salvinorin Aand its synthetic derivatives is crucial in determining
the propercompound to selectfor specific therapies. Direct comparisons between synthetic and
natural kappa opioid agonists must be studied prior to classifying them as interchangeable.
In conclusion, the present study demonstrated that salvinorin A(0.4 mg/kg) attenuated
morphine-induced locomotor activity during CPP, but this dose of salvinorin A was not able to

mitigate morphine-induced conditioned place preference. These results highlight KOR and MOR
interaction on only one of two distinct behavioral effects, implying that different factors are involved

in reward processing and drug-stimulated locomotoractivity. In addition, experiment 2 found that
salvinorin A establishes modest conditioned place aversion and the vehicle DMSO established

significant conditioned place aversion, but neither DMSO nor ethanol/TWEEN80/water influenced
the place conditioning of salvinorin A.
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